TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2478336

Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen
Number of subjects: 39

Group type: COMPARATOR
Intervention: 500 mg naproxen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39
Study: 968923

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (17‐ethinyl 1,3,5‐estratriene 3,17 diol)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Combination therapy (90 mg estradiol valerianate and 300 mg 17‐hydroxy‐19‐norprogesterone caproate)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 82
Study: 31401786

Group type: EXPERIMENTAL
Intervention: Pirfenidone (2403 mg/day)
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study: 28590143

Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise (CRAE) training for 12 weeks, 3 times per week
Number of subjects: 40
Study: 25536215

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant
Number of subjects: 150

Group type: COMPARATOR
Intervention: No allogeneic hematopoietic cell transplant
Number of subjects: 150
Study: 23537403

Group type: EXPERIMENTAL
Intervention: Legflow(®) paclitaxel eluting balloon with nitinol stenting
Number of subjects: 176

Group type: COMPARATOR
Intervention: Uncoated balloon angioplasty with nitinol stenting
Number of subjects: 176
Study: 21851167

Group type: EXPERIMENTAL
Intervention: Taprenepag isopropyl (0.0025%, 0.005%, 0.01%, 0.015%, 0.02%, 0.03%)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Taprenepag isopropyl (0.005%, 0.01%, 0.015%) in unfixed combination with latanoprost 0.005%
Number of subjects: 317

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 317

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Taprenepag isopropyl (0.005%, 0.01%, 0.015%)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 317
Study: 19419362

Group type: EXPERIMENTAL
Intervention: Walking to the toilet (toilet group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Using a bedpan (bedpan group)
Number of subjects: 62
Study: 16394684

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 15763852

Group type: EXPERIMENTAL
Intervention: New curriculum with specified topics, a course book, and a case-based active learning session
Number of subjects: 614
Study: 11165312

Group type: EXPERIMENTAL
Intervention: Interview-based ratings of negative symptoms (measured by the Brief Psychiatric Rating Scale and the Positive and Negative Syndrome Scale)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Interview-based ratings of negative symptoms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Office-based ratings of negative symptoms
Number of subjects: 35
Study: 9051282

Group type: EXPERIMENTAL
Intervention: Psychological therapies for generalized anxiety disorder
Number of subjects: 0
Study: 8369100

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3079992

Group type: EXPERIMENTAL
Intervention: Semiocclusive dressings
Number of subjects: 0
Study: 29743087

Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (0.3 g/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (1.3 g/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EPA+α‐LA (1.3 g/d + 0.3 g/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 29441923

Group type: EXPERIMENTAL
Intervention: Belinal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acarbose (active control)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24503285

Group type: EXPERIMENTAL
Intervention: high-frequency rTMS to the right DLPFC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 22932325

Group type: EXPERIMENTAL
Intervention: FEMTO LDV femtosecond laser with intended flap thickness of 90 µm
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: FEMTO LDV femtosecond laser with intended flap thickness of 110 µm
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: FEMTO LDV femtosecond laser
Number of subjects: 130
Study: 19092847

Group type: EXPERIMENTAL
Intervention: Resistance training with quick lifting and slow lowering (ERT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training with slow lifting and quick lowering (CRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary group (SED)
Number of subjects: 30
Study: 17151341

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus stimulation (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Optimized medical treatment (n = 10)
Number of subjects: 20
Study: 14726931

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rEpo) recipients
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 480
Study: 11590509

Group type: EXPERIMENTAL
Intervention: HAART therapy (including indinavir or ritonavir or hard-gel saquinavir-containing regimens)
Number of subjects: 168
Study: 9781603

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg twice daily by mouth
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of CF at 20 mg/m2 IV push, 5-FU at 325 mg/m2 IV daily for 5 days/week, and interferon alpha-2A 5 x 10(6) units/m2 SC on days 1, 3, 5
Number of subjects: 31
Study: 7886777

Group type: EXPERIMENTAL
Intervention: 12 mg aminosidine base/kg/d for 7 d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 12 mg/kg/d for 14 d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 18 mg/kg/d for 14 d
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 2963059

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol combined with ipratropium bromide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inhaled salbutamol alone
Number of subjects: 25
Study: 6965579

Group type: EXPERIMENTAL
Intervention: Propranolol, 10 mg orally every 6 hours
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study: 31043773

Group type: EXPERIMENTAL
Intervention: semirigid thoracolumbar orthosis
Number of subjects: 15
Study: 28560782

Group type: EXPERIMENTAL
Intervention: C3BS‐CQR‐1 (cardiopoietic mesenchymal stem cells)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 351
Study: 25299463

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23485605

Group type: EXPERIMENTAL
Intervention: Slight chamfer (CHA, n = 10)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Knife-edge (KNE, n = 10)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Shoulder (SHO, n = 10, control)
Number of subjects: 90
Study: 21378603

Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study: 19228754

Group type: EXPERIMENTAL
Intervention: Haemofiltration
Number of subjects: 206

Group type: COMPARATOR
Intervention: Haemodiafiltration
Number of subjects: 206
Study: 17560875

Group type: EXPERIMENTAL
Intervention: Stenting with GuardWire distal protection
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion (<2 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Time to reperfusion (2 to 3 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Time to reperfusion (>3 to 4 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Time to reperfusion (>4 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (<2 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (2 to 3 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (>3 to 4 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (>4 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (<2 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (2 to 3 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (>3 to 4 hours)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (>4 hours)
Number of subjects: 501
Study: 15379146

Group type: EXPERIMENTAL
Intervention: LAC250 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: LAC500 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: LAC250
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: LAC500
Number of subjects: 235
Study: 11451214

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (2.5-80 mg)
Number of subjects: 3095

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (20 mg and above)
Number of subjects: 3095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3095
Study: 9714484

Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia in patients with RCA lesion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antegrade or retrograde cardioplegia in patients without RCA lesion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with RCA lesion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Increasing number of preoperative infarcts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: More advanced coronary artery disease
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prolonged stay in the intensive care unit
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Occurrence of postoperative ventricular tachycardia
Number of subjects: 60
Study: 8066909

Group type: COMPARATOR
Intervention: Normal dose of budesonide via Nebuhaler
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Half normal dose of budesonide via Turbuhaler
Number of subjects: 241
Study: 3058131

Group type: EXPERIMENTAL
Intervention: Salbutamol dry powder inhaled from Salbutamol cyclocaps Pharbita 0.4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 0
Study: 1126349

Group type: EXPERIMENTAL
Intervention: Evaluation of adaptiveness and appropriateness of mental retardation label by teachers
Number of subjects: 288
Study: 31048638

Group type: EXPERIMENTAL
Intervention: Combined Ahmed Glaucoma Valve (AGV) implantation and trabeculectomy revision with adjunctive antimetabolite
Number of subjects: 20

Group type: COMPARATOR
Intervention: AGV implantation alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined AGV implantation and trabeculectomy revision with adjunctive antimetabolite
Number of subjects: 20
Study: 27908840

Group type: EXPERIMENTAL
Intervention: Taper support intervention (psychiatric consultation, opioid dose tapering, and 18 weekly meetings with a physician assistant)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Taper support intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study: 26065500

Group type: EXPERIMENTAL
Intervention: 5% natamycin (Group A)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 200mg oral ketoconazole twice a day plus 5% natamycin (Group B)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 115
Study: 23150531

Group type: EXPERIMENTAL
Intervention: Journey DPP
Number of subjects: 64

Group type: COMPARATOR
Intervention: Health-oriented comparison condition
Number of subjects: 64
Study: 21377888

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (0.1 ml/kg bolus followed by 0.1 ml/kg/h continuous infusion for 48 hours)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline (0.1 ml/kg bolus followed by 0.1 ml/kg/h continuous infusion for 48 hours)
Number of subjects: 47
Study: 19594906

Group type: EXPERIMENTAL
Intervention: e‐SBI with limited feedback
Number of subjects: 2858

Group type: COMPARATOR
Intervention: e‐SBI with full feedback
Number of subjects: 2858
Study: 16983674

Group type: EXPERIMENTAL
Intervention: Double-pass, low-energy treatment (8-11 J/cm²)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Single-pass, high-energy treatment (13-14 J/cm²)
Number of subjects: 6
Study: 14972421

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600mg orally t.i.d.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 80
Study: 11519636

Group type: EXPERIMENTAL
Intervention: Cocaine (200 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methylphenidate (15-90 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Triazolam (0.125-0.75 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9762776

Group type: EXPERIMENTAL
Intervention: Specific IgA antibodies to Dermatophagoides farinae
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Specific IgA antibodies to Streptococcus pneumoniae
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Specific IgG antibodies to Dermatophagoides farinae
Number of subjects: 28

Group type: COMPARATOR
Intervention: Specific IgG antibodies to Streptococcus pneumoniae
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) levels
Number of subjects: 28
Study: 8158764

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15‐keto‐13,14‐dihydro‐prostaglandin E1 (metabolite of Prostaglandin E1)
Number of subjects: 0
Study: 3354494

Group type: EXPERIMENTAL
Intervention: 50 g of fructose
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 g of glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fructose or glucose in a mixed meal format
Number of subjects: 0
Study: 31650181

Group type: EXPERIMENTAL
Intervention: Higher serum calcium levels (measured as standard deviation increase)
Number of subjects: 11034

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to higher serum calcium levels
Number of subjects: 11034
Study: 30056030

Group type: EXPERIMENTAL
Intervention: 600 mg risankizumab every 4 weeks for 12 weeks (open-label intravenous therapy)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous risankizumab (180 mg) every 8 weeks for 26 weeks (maintenance phase)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Open-label intravenous risankizumab (600 mg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous risankizumab (180 mg)
Number of subjects: 108
Study: 28116804

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 26447746

Group type: COMPARATOR
Intervention: Blocked practice schedule (low contextual interference)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Random practice schedule (high contextual interference)
Number of subjects: 40
Study: 24126646

Group type: EXPERIMENTAL
Intervention: MARS with conventional treatment (n = 53)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional treatment (n = 49)
Number of subjects: 102
Study: 21553346

Group type: EXPERIMENTAL
Intervention: Project Support intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Existing services comparison condition
Number of subjects: 66
Study: 18451376

Group type: EXPERIMENTAL
Intervention: Fluoride treatment (1.23 percent sodium fluoride)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17198066

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP) tablets
Number of subjects: 845

Group type: COMPARATOR
Intervention: 4-L polyethylene glycol (PEG) solution
Number of subjects: 845
Study: 12975595

Group type: EXPERIMENTAL
Intervention: Quinapril (titrated to 40 mg/day) for 6 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 10752751

Group type: EXPERIMENTAL
Intervention: 5N15 glutamine in children with severe burns
Number of subjects: 5

Group type: COMPARATOR
Intervention: Elective scar reconstruction (control group)
Number of subjects: 5
Study: 8884414

Group type: EXPERIMENTAL
Intervention: Isometric exercise (neutral ankle angle)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Concentric exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 12
Study: 1587378

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated estrogens cyclically (CE; 25 days/month)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated estrogens continuously
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 50 micrograms/day of transdermal 17 beta‐estradiol cyclically (24 days/month)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Treatment-free control group
Number of subjects: 84
Study: 3983885

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 1.25 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 2.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (oxygen and corticosteroid treatment withheld)
Number of subjects: 32
Study: 30417851

Group type: EXPERIMENTAL
Intervention: Ketofol 1:1 mixture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketofol 1:2 mixture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketofol 1:4 mixture
Number of subjects: 90
Study: 26638048

Group type: EXPERIMENTAL
Intervention: External focus
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Internal focus
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 24851869

Group type: EXPERIMENTAL
Intervention: Pneumoconiosis patients
Number of subjects: 19
Study: 23080237

Group type: EXPERIMENTAL
Intervention: Silver alginate powder dressing
Number of subjects: 34

Group type: COMPARATOR
Intervention: Foam dressing (control)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison of silver alginate powder vs foam dressing
Number of subjects: 34
Study: 20302428

Group type: EXPERIMENTAL
Intervention: Case patients with VAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control patients without VAP
Number of subjects: 30
Study: 18593851

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LPS + Oxytocin
Number of subjects: 10
Study: 16033247

Group type: EXPERIMENTAL
Intervention: 3% cork extract gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 15
Study: 12445027

Group type: COMPARATOR
Intervention: Co-artemether (artemether-lumefantrine) alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Co-artemether with ketoconazole (400 mg on day 1 followed by 200 mg o.d. for 4 additional days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Co-artemether with ketoconazole
Number of subjects: 16
Study: 10337542

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8938003

Group type: EXPERIMENTAL
Intervention: Long row of evenly spaced dots presented in counterphase with a blank interval of 15 ms between frames
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long row of evenly spaced dots presented in counterphase with luminance polarity reversed on successive frames
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dot displaced over small distances under the same conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long row of displaced dots with weakened activation of motion detectors
Number of subjects: 0
Study: 1743751

Group type: EXPERIMENTAL
Intervention: Lincomycin 300 mg intramuscularly daily in a single dose
Number of subjects: 150
Study: 6852325

Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream applied once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream applied twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream applied every alternate day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream with an initial three times daily loading dose on the first day
Number of subjects: 10
Study: 31315515

Group type: EXPERIMENTAL
Intervention: Bilateral contralaterally controlled functional electrical stimulation (CCFES)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unilateral cyclic neuromuscular electrical stimulation (cNMES)
Number of subjects: 15
Study: 30138015

Group type: EXPERIMENTAL
Intervention: Naltrexone plus brief counseling
Number of subjects: 128
Study: 26885762

Group type: EXPERIMENTAL
Intervention: Nitrate-rich (NR) supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nitrate-poor (NP) supplementation
Number of subjects: 14
Study: 25316112

Group type: EXPERIMENTAL
Intervention: Warmed fluids
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Warmed underbody pad
Number of subjects: 226

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study: 22512509

Group type: EXPERIMENTAL
Intervention: 12 NB‐UVB exposures over 4 weeks (mean cumulative dose 48·4 standard erythema doses)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 20 μg of oral cholecalciferol daily for 4 weeks
Number of subjects: 63
Study: 19914567

Group type: EXPERIMENTAL
Intervention: Various interventions from reviewed RCTs
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group interventions from reviewed RCTs
Number of subjects: 78